Sign up online today & collaborate
or click here to find out more
Personalized medicine is the next thing and immunotherapy expert BioNTech is determined to build its place in this competitive field. With this purpose in mind, the German biotech will partner withSiemens to build a new production plant for personalized cancer vaccines.
Founded in 2008, the BioNTech Group has become one of the fastest-growing biotechnology companies in Europe. Its secret? The development of higly-needed novel biopharmaceuticals. The German biotech has signed strategic collaborations in the past few months in the immuno-oncology field, namely with Genmaband Eli Lilly, for instance. Thanks to the last of these partnerships, BioNTech will develop a new manufacturing site for cancer vaccines. To this aim, the company will count with Siemens’ help.
For more click here